StockTipsArenaBeta

BUY Lupin Limited — Sharekhan Research

BUYLupin Limited
Lupin share price target & all analyst calls

bySharekhan ResearchHorizon: NA (inferred 1 year)21 Aug 2025via Institutional / Brokerage Research

Entry₹1,962.5Inferred
Target₹2,400
Total upside +22.29% (call closed)
Stop lossNot given
Exit₹2,4006 May 2026, 12:05 pm
Target hit+22.29%0.00%upside left
Follow Sharekhan Research for new calls(55% target hit, 443 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 12 active Long-term calls on LUPINSee 274 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 10:59 am IST
5 supporting0 opposing
Supports the BUY call (5)

Lupin Limited has received approval from the U.S. Food and Drug Administration (FDA) for its Glycerol Phenylbutyrate Oral Liquid.

BSE · Company Update·5 May · yesterday

(opens in new tab)

2 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·4 May · yesterday

Lupin Limited has launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States.

BSE · Company Update·22 Apr · 2w ago

(opens in new tab)

3 other SEBI-registered advisors have active long-term BUY calls on this stock

Advisor consensus · same horizon·16 Feb · 3mo ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Lupin

All analyst calls on Lupin

More from Sharekhan Research

Every call and its outcome